Differential transferrin receptor density in human colorectal cancer: A potential probe for diagnosis and therapy.

Prost, A.; Ménégaux, Florence; Langlois, P; Vidal, Joana; Koulibaly, M; Jost, J L; Duron, Jean‐Jacques; Chigot, Jean-Paul; Vayre, P; Aurengo, André; Legrand, J.C.; Rosselin, G; Gespach, Christian

doi:10.3892/ijo.13.4.871

Cited by 24 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25,55 Because of the pivotal role of TfR in Fe uptake, the TfR is more abundantly expressed in rapidly dividing cells than quiescent cells, 56,57 and high levels of TfR expression have been identified on many tumors. [58][59][60] In fact, studies have shown that expression of TfR is more abundant in breast cancer tissue than in normal tissue. 60,61 Given the facts that estrogen and Fe exert their biological effects through their receptors, 62,63 it is important to know whether E2 affects TfR in cells with different ER and PR status.…”

Section: Discussionmentioning

confidence: 99%

Roles of hormone replacement therapy and iron in proliferation of breast epithelial cells with different estrogen and progesterone receptor status

et al. 2008

View full text Add to dashboard Cite

Estrogen and iron play critical roles in a female body development and were investigated in the present study in relation to in vitro cell proliferation. Prempro™, a hormone replacement therapy drug, and 17β-estradiol (E2) were shown to increase cell proliferations in estrogen receptor positive (ER + ) cells independent of progesterone receptor (PR) status. For example, increased cell proliferation was observed in ER + /PR + human breast cancer MCF-7, its matching non-cancerous human breast epithelial MCF-12A, and ER + /PR + murine mammary cancer MXT + cells, but not in ER − /PR − MDA-MB-231, its matching non-cancerous MCF-10A, and MXT − (ER − /PR + ) cells. By mimicking post-menopausal conditions of high estrogen in local breast tissue and increased iron levels due to cessation of menstrual periods, E2 and iron were shown to exert synergistic effects on proliferation of MCF-7 cells and significantly increased Ki67 and proliferating cell nuclear antigen. Western blotting of E2-treated ER + but not ER − cells showed that E2 also increased transferrin receptor (TfR). Further studies are needed to assess the mitogenic effects of iron and estrogen in normal post-menopausal breast.

show abstract

Section: Discussionmentioning

confidence: 99%

Roles of hormone replacement therapy and iron in proliferation of breast epithelial cells with different estrogen and progesterone receptor status

et al. 2008

View full text Add to dashboard Cite

show abstract

“…In normal tissues, constitutive expression of the TfR is limited to the liver, epidermis, intestinal epithelium, vascular endothelium of brain capillary, and certain populations of blood cells in the bone marrow (5)(6)(7)(8)(9). In contrast, high levels of TfR expression have been identified on many tumors (5,(10)(11)(12)(13)(14)(15). In fact, studies have shown that the TfR is expressed more abundantly in malignant tissues than their normal counterparts (5,13,16,17).…”

mentioning

confidence: 92%

“…In contrast, high levels of TfR expression have been identified on many tumors (5,(10)(11)(12)(13)(14)(15). In fact, studies have shown that the TfR is expressed more abundantly in malignant tissues than their normal counterparts (5,13,16,17). Therefore, the TfR expressed on tumor cells should be suitable for the delivery of therapeutics into cancer cells by receptor-mediated endocytosis.…”

mentioning

confidence: 97%

An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells

Cruz

Sorour

et al. 2002

Proc. Natl. Acad. Sci. U.S.A.

120

View full text Add to dashboard Cite

We have developed an antibody fusion protein (anti-rat TfR IgG3-Av) with the ability to deliver different molecules into cancer cells. It consists of avidin genetically fused to the CH3 region of a human IgG3 specific for the rat transferrin receptor. It forms strong, noncovalent interactions with biotinylated molecules such as glucose oxidase and ␤-galactosidase, and delivers them into the rat myeloma cell line Y3-Ag1.2.3 through receptor-mediated endocytosis. Importantly, the ␤-galactosidase retains activity after internalization. Furthermore, we have unexpectedly discovered that anti-rat TfR IgG3-Av, but not a recombinant anti-rat TfR IgG3 or a nonspecific IgG3-Av, possesses proapoptotic activities against Y3-Ag1.2.3 and the rat T cell lymphoma cell line C58 (NT) D.1.G.OVAR.1. These activities were not observed in two rat cell lines of nonhematopoietic lineage (bladder carcinoma BC47 and gliosarcoma9L).Anti-humanTfRIgG3-Avalsodemonstratedproapoptotic activity against the human erythroleukemia cell line K562. Studies showed that anti-rat TfR IgG3-Av exists as a dimer, suggesting that cross-linking of the surface transferrin receptor may be responsible for the cytotoxic activity. These findings demonstrate that it is possible to transform an antibody specific for a growth factor receptor that does not exhibit inhibitory activity into a drug with significant intrinsic cytotoxic activity against selected cells by fusing it with avidin. The antitumor activity may be enhanced by delivering biotinylated therapeutics into cancer cells. Further development of this technology may lead to effective therapeutics for in vivo eradication of hematological malignancies, and ex vivo purging of cancer cells in autologous transplantation.

show abstract

“…As iron is vital to cellular proliferation, cancer cells exhibit a higher level of surface transferrin receptors than normal cells (Richardson and Baker, 1990;Richardson and Baker, 1992;Trinder et al, 1996;Kalinowski and Richardson, 2005). It is believed that there may be up to a 100-fold higher level of expression of transferrin receptor on the surface of cancer cells than on normal cells (Prost et al, 1998;Shinohara et al, 2000;Gomme et al, 2005;Daniels et al, 2006). Due to its surface accessibility, ability to internalize, and its significant role in human cancer pathology, the transferrin receptor makes an appealing target for cancer treatment.…”

Section: B Active Targetingmentioning

confidence: 99%

Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come

2016

View full text Add to dashboard Cite

Differential transferrin receptor density in human colorectal cancer: A potential probe for diagnosis and therapy.

Cited by 24 publications

References 0 publications

Roles of hormone replacement therapy and iron in proliferation of breast epithelial cells with different estrogen and progesterone receptor status

Roles of hormone replacement therapy and iron in proliferation of breast epithelial cells with different estrogen and progesterone receptor status

An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells

Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come

Contact Info

Product

Resources

About